753 reports of this reaction
1.7% of all AFLIBERCEPT reports
#16 most reported adverse reaction
INTRAOCULAR PRESSURE INCREASED is the #16 most commonly reported adverse reaction for AFLIBERCEPT, manufactured by Regeneron Pharmaceuticals, Inc.. There are 753 FDA adverse event reports linking AFLIBERCEPT to INTRAOCULAR PRESSURE INCREASED. This represents approximately 1.7% of all 43,844 adverse event reports for this drug.
Patients taking AFLIBERCEPT who experience intraocular pressure increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INTRAOCULAR PRESSURE INCREASED is a less commonly reported adverse event for AFLIBERCEPT, but still significant enough to appear in the safety profile.
In addition to intraocular pressure increased, the following adverse reactions have been reported for AFLIBERCEPT:
The following drugs have also been linked to intraocular pressure increased in FDA adverse event reports:
INTRAOCULAR PRESSURE INCREASED has been reported as an adverse event in 753 FDA reports for AFLIBERCEPT. This does not prove causation, but indicates an association observed in post-market surveillance data.
INTRAOCULAR PRESSURE INCREASED accounts for approximately 1.7% of all adverse event reports for AFLIBERCEPT, making it a notable side effect.
If you experience intraocular pressure increased while taking AFLIBERCEPT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.